HISTOGEN INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2 USD | 0.00% |
|
0.00% | -35.00% |
| Apr. 19 | Subchapter V Trustee Appointed Under Chapter 11 for Histogen Inc. | CI |
| Apr. 18 | Histogen Inc. Filed for Bankruptcy | CI |
Presentation Operator MessageOperator (Operator)Welcome to the Conatus Pharmaceuticals Financi...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Histogen Inc. is a clinical-stage therapeutics company. The Company is focused on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the bodyâs natural process to restore immune function. Its product candidates include emricasan, CTS-2090 and CTS-2096. It develops emricasan for acute bacterial skin and skin structure infections (ABSSSI) as well evaluating its use for other infectious diseases. Its pipeline also includes novel preclinical product candidates including CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases. Emricasan is an orally available pan-caspase inhibitor designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. CTS-2090 and CTS-2096 are selective caspase-1 inhibitors targeting inflammasome activation and to treat a variety of inflammation mediated diseases.
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -35.00% | 854K | |
| +7.29% | 111B | |
| +11.20% | 106B | |
| -12.48% | 22.24B | |
| +0.44% | 21.25B | |
| -4.18% | 18.97B | |
| -37.85% | 18.52B | |
| -8.56% | 16.81B | |
| +37.62% | 12.54B | |
| -24.25% | 8.09B |
- Stock Market
- Equities
- HSTO Stock
- News Histogen Inc.
- Transcript : Conatus Pharmaceuticals Inc., Q4 2017 Earnings Call, Mar 07, 2018
